Nobilamides A-H, Long-Acting Transient Receptor Potential Vanilloid-1 (TRPV1) Antagonists from Mollusk-Associated Bacteria

被引:32
|
作者
Lin, Zhenjian [1 ]
Reilly, Christopher A. [2 ]
Antemano, Rowena [4 ]
Hughen, Ronald W. [3 ]
Marett, Lenny [1 ]
Concepcion, Gisela P. [4 ]
Haygood, Margo G. [5 ]
Olivera, Baldomero M. [6 ]
Light, Alan [3 ]
Schmidt, Eric W. [1 ,6 ]
机构
[1] Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA
[2] Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA
[3] Univ Utah, Dept Anesthesiol, Salt Lake City, UT 84112 USA
[4] Univ Philippines, Inst Marine Sci, Quezon City 1101, Philippines
[5] Oregon Hlth & Sci Univ, OGI Sch Sci & Engn, Dept Environm & Biomol Syst, Beaverton, OR 97006 USA
[6] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA
关键词
CAPSAICIN RECEPTOR; ION-CHANNEL; CELL-DEATH; EPITHELIAL-CELLS; ACTIVATION; SENSITIZE; CYSTEINE; TL-119; ACIDS;
D O I
10.1021/jm101621u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
New compounds nobilamides A-H and related known compounds A-3302-A and A-3302-B were isolated based upon their suppression of capsaicin-induced calcium uptake in a mouse dorsal root ganglion primary cell culture assay. Two of these compounds, nobilamide B and A-3302-A, were shown to be long-acting antagonists of mouse and human TRPV1 channels, abolishing activity for >1 h after removal of drug presumably via a covalent attachment. Other derivatives also inhibited the TRPV1 channel, albeit with low potency, affording a structure-activity profile to support the proposed mechanism of action. While the activities were modest, we propose a new mechanism of action and a new site of binding for these inhibitors that may spur development of related analogues for treatment of pain.
引用
收藏
页码:3746 / 3755
页数:10
相关论文
共 50 条
  • [1] Transient Receptor Potential Vanilloid-1 (TRPV1) Is a Mediator of Lung Toxicity for Coal Fly Ash Particulate Material
    Deering-Rice, Cassandra E.
    Johansen, Mark E.
    Roberts, Jessica K.
    Thomas, Karen C.
    Romero, Erin G.
    Lee, Jeewoo
    Yost, Garold S.
    Veranth, John M.
    Reilly, Christopher A.
    MOLECULAR PHARMACOLOGY, 2012, 81 (03) : 411 - 419
  • [2] Transient receptor potential vanilloid-1 (TRPV1) channels act as suppressors of the growth of glioma
    Cheng, Jingjing
    Zeng, Mengliu
    Peng, Biwen
    Li, Ping
    Zhao, Shiyu
    BRAIN RESEARCH BULLETIN, 2024, 211
  • [3] Discovery of novel pyrrolopyridazine scaffolds as transient receptor potential vanilloid (TRPV1) antagonists
    Dorange, Ismet
    Forsblom, Rickard
    Macsari, Istvan
    Svensson, Mats
    Bylund, Johan
    Besidski, Yevgeni
    Blid, Jan
    Sohn, Daniel
    Gravenfors, Ylva
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (22) : 6888 - 6895
  • [4] In vitro characterization of the thermoneutral transient receptor potential vanilloid-1 (TRPV1) inhibitor GRTE16523
    Damann, Nils
    Bahrenberg, Gregor
    Stockhausen, Hannelore
    Habermann, Christopher J.
    Lesch, Bernhard
    Frank-Foltyn, Robert
    Lee, Jeewoo
    Ann, Jihyae
    Christoph, Thomas
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 871
  • [5] Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature
    Voight, Eric A.
    Kort, Michael E.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (09) : 1107 - 1122
  • [6] Vascular Expression of Transient Receptor Potential Vanilloid 1 (TRPV1)
    Sand, Claire A.
    Grant, Andrew D.
    Nandi, Manasi
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2015, 63 (06) : 449 - 453
  • [7] Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists
    Blum, Charles A.
    Caldwell, Timothy
    Zheng, Xiaozhang
    Bakthavatchalam, Rajagopal
    Capitosti, Scott
    Brielmann, Harry
    De Lombaert, Stephane
    Kershaw, Mark T.
    Matson, David
    Krause, James E.
    Cortright, Daniel
    Crandall, Marci
    Martin, William J.
    Murphy, Beth Ann
    Boyce, Susan
    Jones, A. Brian
    Mason, Glenn
    Rycroft, Wayne
    Perrett, Helen
    Conley, Rachael
    Burnaby-Davies, Nicola
    Chenard, Bertrand L.
    Hodgetts, Kevin J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (08) : 3330 - 3348
  • [8] Transient receptor potential vanilloid 1 (TRPV1), TRPV4, and the kidney
    Kassmann, M.
    Harteneck, C.
    Zhu, Z.
    Nuernberg, B.
    Tepel, M.
    Gollasch, M.
    ACTA PHYSIOLOGICA, 2013, 207 (03) : 546 - 564
  • [9] Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis
    Garami, Andras
    Shimansky, Yury P.
    Rumbus, Zoltan
    Vizin, Robson C. L.
    Farkas, Nelli
    Hegyi, Judit
    Szakacs, Zsolt
    Solymar, Margit
    Csenkey, Alexandra
    Chiche, Dan A.
    Kapil, Ram
    Kyle, Donald J.
    Van Horn, Wade D.
    Hegyi, Peter
    Romanovsky, Andrej A.
    PHARMACOLOGY & THERAPEUTICS, 2020, 208
  • [10] Novel Radiolabeled Vanilloid with Enhanced Specificity for Human Transient Receptor Potential Vanilloid 1 (TRPV1)
    Pearce, Larry V.
    Ann, Jihyae
    Jung, Aeran
    Thorat, Shiyaii A.
    Herold, Brienna K. A.
    Habtemichael, Amelework D.
    Blumberg, Peter M.
    Lee, Jeewoo
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (19) : 8246 - 8252